cyclopentyl(methyl)carbamic chloride | 1383546-51-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: cyclopentyl(methyl)carbamic chloride
• 英文别名: N-methylcyclopentylcarbamoyl chloride；N-cyclopentyl-N-methylcarbamoyl chloride
• CAS: 1383546-51-7
• 化学式: C₇H₁₂ClNO
• mdl: MFCD23790130
• 分子量: 161.631
• InChiKey: SUXDLDZKUQQCNZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  cyclopentyl(methyl)carbamic chloride 在 palladium 10% on activated carbon 、 氢气 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醇 、 水 、 溶剂黄146 、 乙酸乙酯 、 mineral oil 为溶剂， 反应 3.5h， 生成 N-cyclopentyl-N-methyl-4-(3-ureidophenyl)-1H-imidazole-1-carboxamide
  参考文献：
  名称：

  [EN] UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS
  [FR] COMPOSÉS D'URÉE ET LEUR UTILISATION EN TANT QU'INHIBITEURS D'ENZYME

  摘要：

  公开号：

  WO2014017936A3
• 作为产物：
  描述：

  N-环戊基氨基甲酸乙酯 在 lithium aluminium tetrahydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.5h， 生成 cyclopentyl(methyl)carbamic chloride
  参考文献：
  名称：

  [EN] PROCESSES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS
  [FR] PROCÉDÉS DE SYNTHÈSE DE COMPOSÉS D'URÉE SUBSTITUÉS

  摘要：

  公开号：

  WO2015112036A3

文献信息

• Tetrazolinones as herbicides and intermediates
  申请人：NIHON BAYER AGROCHEM K.K.

  公开号：EP0820994A1

  公开（公告）日：1998-01-28

  The present invention relates to novel compounds and mixtures of geometrical isomers, which are represented by the formula: wherein R1 and R2independently of one another are C1-6 alkyl, C1-6 haloalkyl, C3-8 cycloalkyl, C2-6 alkenyl, C2-6 haloalkenyl, C3-6 alkynyl or optionally substituted phenyl; or R1 and R2, together with the nitrogen atom to which they are bonded, form a 5-membered or 6-membered heterocyclic ring which may be benzo-fused or which may be substituted by halogen or C1-4 alkyl; R3 is hydrogen or C1-6 alkyl; R4 is hydrogen or C1-6 alkyl; or R3 and R4, together with the carbon atoms to which they are bonded, form cyclopentylidene or cyclohexylidene; and R5 is C1-6 alkyl, C3-6 alkenyl or benzyl; further to processes and new intermediates for their production and to their use as herbicides.

  本发明涉及一类新的化合物及几何异构体的混合物，其由以下公式表示：其中R1和R2彼此独立地为C1-6烷基，C1-6卤代烷基，C3-8环烷基，C2-6烯基，C2-6卤代烯基，C3-6炔基或可选地被取代的苯基；或者R1和R2与它们所连接的氮原子一起形成一个可能被苯并环合的、5成员或6成员的杂环环，该环可能被卤素或C1-4烷基取代；R3是氢或C1-6烷基；R4是氢或C1-6烷基；或者R3和R4与它们所连接的碳原子一起形成环戊基亚基或环己基亚基；并且R5是C1-6烷基，C3-6烯基或苄基；进一步涉及到它们的制备过程和新中间体，以及它们作为除草剂的使用。
• 7-AZAINDOLE OR 4,7-DIAZAINDOLE DERIVATIVES AS IKK EPSILON AND TBK1 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：GREEN CROSS CORPORATION

  公开号：US20160297815A1

  公开（公告）日：2016-10-13

  Provided are 7-azaindole or 4,7-diazaindole derivatives as an IKKε (I-kappa-B kinase epsilon) and TBK1 (TANK-binding kinase 1) inhibitor. The 7-azaindole or 4,7-diazaindole derivative effectively inhibits IKKε and TBK1, and thus is useful not only as an anticancer agent for the treatment of various cancers including colorectal cancer, breast cancer, CNS cancer, colon cancer, non-small cell lung cancer, kidney cancer, prostate cancer, ovarian cancer, uterus cancer, stomach cancer, liver cancer, skin cancer, lung cancer, brain cancer, bladder cancer, esophageal cancer, pancreatic cancer, thyroid cancer, head and neck cancer, squamous cell carcinoma, osteosarcoma, B-cell or T-cell lymphoma, acute or chronic leukemia and multiple myeloma, but as a therapeutic agent for chronic inflammation.

  提供了7-氮杂吲哚或4,7-二氮杂吲哚衍生物作为IKKε（I-卡帕B激酶ε）和TBK1（TANK结合激酶1）抑制剂。7-氮杂吲哚或4,7-二氮杂吲哚衍生物有效地抑制IKKε和TBK1，因此不仅可用作抗癌剂治疗各种癌症，包括结直肠癌、乳腺癌、中枢神经系统癌、结肠癌、非小细胞肺癌、肾癌、前列腺癌、卵巢癌、子宫癌、胃癌、肝癌、皮肤癌、肺癌、脑癌、膀胱癌、食管癌、胰腺癌、甲状腺癌、头颈癌、鳞状细胞癌、骨肉瘤、B细胞或T细胞淋巴瘤、急性或慢性白血病和多发性骨髓瘤，还可作为慢性炎症的治疗剂。
• [EN] INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES<br/>[FR] INGÉNOL-3-ACYLATES III ET INGÉNOL-3-CARBAMATES
  申请人：LEO PHARMA AS

  公开号：WO2012083953A1

  公开（公告）日：2012-06-28

  The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is -NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

  该发明涉及一般式I的化合物，其中R为杂环芳基，可选择地由R7取代；或R为杂环烷基或杂环烯基，可选择地由R8取代；或R为X，其中X为-NR11R12；以及其在治疗中的药物可接受的盐、水合物或溶剂合物，用于单独使用或与一个或多个其他药用活性化合物结合在一起，用于预防、治疗或改善对中性粒细胞氧化爆发的刺激响应、对角质细胞IL-8释放的刺激响应或对坏死诱导的刺激响应的疾病或症状。
• INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES
  申请人：Grue-Sørensen Gunnar

  公开号：US20140303150A1

  公开（公告）日：2014-10-09

  The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

  本发明涉及一般式I的化合物，其中R是杂环芳基，可选择由R7取代; 或R是杂环烷基或杂环烯基，可选择由R8取代; 或R是X，其中X是—NR11R12;以及其药学上可接受的盐、水合物或溶剂化物，用于治疗，单独或与一个或多个其他药学活性化合物联合使用，预防、治疗或改善对嗜中性粒细胞氧化爆发刺激、对角质细胞IL-8释放刺激或对坏死诱导反应的疾病或病情的响应。
• UREA COMPOUNDS AND THEIR USE AS ENZYME INHIBITORS
  申请人：BIAL-PORTELA & CA, S.A.

  公开号：US20150174103A1

  公开（公告）日：2015-06-25

  A compound having the following structure: or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

  一种具有以下结构的化合物：或其药学上可接受的盐或衍生物。该化合物可用于治疗或预防以下疾病：食欲调节、肥胖症、代谢紊乱、消瘦、厌食症、疼痛、炎症、神经毒性、神经创伤、中风、多发性硬化、脊髓损伤、帕金森病、左旋多巴诱发的运动障碍、亨廷顿病、吉尔·德·拉·图雷特综合征、迟发性运动障碍、肌张力障碍、肌萎缩性侧索硬化症、阿尔茨海默病、癫痫、精神分裂症、焦虑症、抑郁症、失眠、恶心、呕吐、酒精障碍、药物成瘾（如鸦片、尼古丁、可卡因、酒精和精神兴奋剂）、高血压、循环性休克、心肌再灌注损伤、动脉粥样硬化、哮喘、青光眼、视网膜病变、癌症、炎症性肠病、急性和慢性肝病（如肝炎和肝硬化）、关节炎和骨质疏松症。